Valeant (VRX) volatility flat into upgrade to Overweight at Morgan Stanley
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
RBC Capital Remains Sidelined as Valeant Pharma (VRX) Announces Credit Amendment
August 18, 2016 11:15 AM EDTRBC Capital reiterated a Sector Perform rating and $36.00 price target on Valeant Pharmaceuticals (NYSE: VRX) following the company's announcement that is has agreed to amend terms with its lenders. This decision comes on the heels of VRX's Aug 12th announcement that the company would... More
Valeant Pharma (VRX) Ramps to Session Highs Following Analyst Upgrade
August 17, 2016 12:00 PM EDTValeant Pharma (NYSE: VRX) shares are reaching new session highs midday Wednesday. The stock is up well over 13 percent with high volume.
Notably, Morgan Stanley upgraded the stock earlier. For more color on the call, click here.
... More